Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy of Durvalumab plus Regorafenib versus observation for patients with stage IV colorectal cancer achieving the no evidence of disease state. The NED state can be achieved in any line of treatment and it is defined as: 1. R0 resection for surgery, 2. the complete ablation defect covering the lesion on CT scan for radiofrequency, 3. the erogation of ≥ 60 Gy for stereotactic radiotherapy, 4. complete response to antineoplastic treatments on CT scan. In all these cases CEA and CA 19.9 must be within normal limits at the time of randomization. Participants in this study will receive: Experimental arm: Regorafenib 90 mg d1-21 every 28 days plus Durvalumab 1500 mg every 28 days for 1 year Control arm: Observation (crossover to Experimental arm is allowed in case of relapse) Tumor assessment will be performed every 12 weeks.


Clinical Trial Description

The safety run-in phase is planned for the first 4 patients randomized to the experimental arm using a starting dose of 60 mg/die of Regorafenib (and fixed 1500 mg of Durvalumab), to be escalated after 2 months to 90 mg/die if < 2 patients report serious adverse events. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05382741
Study type Interventional
Source Ospedale Policlinico San Martino
Contact Alberto Sobrero, MD
Phone +39 010 555 4386
Email alberto.sobrero@hsanmartino.it
Status Recruiting
Phase Phase 2
Start date March 2, 2022
Completion date March 2, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT03594448 - Detection of MSI in Circulating Tumor DNA of Colorectal Carcinoma Patients
Completed NCT03986541 - AREG, EREG and EGFR: Response to Anti-EGFR Agents in Colorectal Cancer
Completed NCT01570452 - Matrilysin Expression in Different Stages of Colorectal Tumors N/A
Recruiting NCT05354817 - Impact of FOLFIRINOX Chemotherapy in IV Stage Colorectal Cancer Patients Previously Exposed to Irinotecan, Fluoropyrimidine and Oxaliplatin Phase 2
Recruiting NCT05576896 - Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory Phase 2
Completed NCT04715061 - Impact of Aerobic Exercise on Immune Response and Side Effects of Cancer Treatments N/A
Terminated NCT03149679 - The p53 Colorectal Cancer Trial Phase 2
Completed NCT05550701 - Prognostic Impact of Increased Lymph Node Yield in Colorectal Cancer Patients With Synchronous Distant Metastasis: a Population-based Study of the US Database and a Chinese Registry
Enrolling by invitation NCT04149613 - Predictive and Prognostic Value of Inflammatory Markers and microRNA in Stage IV Colorectal Cancer
Completed NCT04425239 - Intermittent or Continuous Panitumumab Plus FOLFIRI for RAS/B-RAF Wild-type Metastatic Colorectal Cancer Phase 2
Completed NCT06329700 - Parenchymal Sparing Hepatectomy in Post-chemotherapy Liver Atrophy
Recruiting NCT06342440 - Early Detection of Advanced Adenomas and Colorectal Cancer
Not yet recruiting NCT04917276 - Treatment Response Prediction System of mCRC Patients Based on CTC
Not yet recruiting NCT06296056 - Phase I Study of Combined Immune Cell Therapy in Patients With Stage 4 Colorectal Cancer With Metastatic Lesion Who Failed Prior Standard of Care Phase 1
Recruiting NCT04714814 - Mechanisms of Fate Evolution of Colorectal Adenocarcinoma Metastasis
Not yet recruiting NCT05451719 - Fruquintinib Plus Capecitabine Versus Capecitabine as Maintenance Therapy for Metastatic Colorectal Cancer After First-line Chemotherapy Phase 2
Completed NCT03031444 - Perioperative Chemotherapy Plus Cetuximab Versus Chemotherapy Alone for High Risk Resectable Colorectal Liver Metastasis Phase 2/Phase 3
Completed NCT05164419 - Impact de la Marge de résection Sur la Survie à Long Terme et le Taux de récidive Des Patients Atteints de Cancers Colorectaux opérés au CHUS Entre 2006 et 2016 Pour Des métastases hépatiques
Recruiting NCT05171660 - Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer Phase 3
Recruiting NCT05426005 - Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer Phase 1/Phase 2